All In Biotech

Drug Trial Radar · NCT02528357

GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)

A Phase I, Open-Label Study of GSK3174998 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Subjects With Selected Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: May 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

141

Actual

Start

Sep 11, 2015

Primary completion

Apr 29, 2020

Study completion Apr 29, 2020

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Aug 19, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first time in human (FTIH), open-label, non-randomized, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary clinical activity of GSK3174998 administered intravenously to participants with selected advanced or recurrent solid tumors. This dose-escalation study will assess the safety, activity of GSK3174998 as monotherapy (Part 1), in combination with pembrolizumab (Part 2), and potentially in combination with additional therapies. The study will be conducted in 2 parts, each part consisting of starting with a dose-escalation phase followed by a cohort expansion phase. GSK3174998 will first be evaluated as monotherapy in escalating doses. Once a dose of GSK3174998 has been identified that is both tolerable and demonstrates pharmacodynamic activity, enrollment of Part 2 may begin. In Part 2, escalating doses of GSK3174998 will be evaluated with fixed doses of pembrolizumab. The maximum duration of treatment with GSK3174998 and pembrolizumab will be approximately 2 years or 35 cycles, whichever comes first. The follow-up period for safety assessments will be a minimum of 3 months from the date of the last dose. The post-treatment follow-up period will include disease assessments every 12 weeks until documented progressive disease (PD). Approximately 141 participants with selected advanced or recurrent solid tumors will be enrolled.

Conditions

  • Neoplasms

Interventions

  • GSK3174998Drug

    Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to \<=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W

  • PembrolizumabDrug

    Pembrolizumab as 100 mg/4 milliliter (mL) solution (dose: 200 mg) to be given as IV infusion for 30 min, Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Any Serious Adverse Event (SAE) and Non-serious Adverse Event (Non-SAE)Time frame: Up to maximum 39 weeks
  2. Part 2A: Number of Participants With Any SAE and Non-SAETime frame: Up to maximum 105 weeks
  3. Part 2B: Number of Participants With Any SAE and Non-SAETime frame: Up to maximum 33 weeks
  4. Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: 28 days
  5. Part 2A: Number of Participants With DLTsTime frame: 28 days
  6. Part 2B: Number of Participants With DLTsTime frame: 28 days
  7. Part 1: Number of Participants With Any Adverse Event Leading to Withdrawal (AELD) From the StudyTime frame: Up to maximum 39 weeks
  8. Part 2A: Number of Participants With Any Adverse Event Leading to Withdrawal From the StudyTime frame: Up to maximum 105 weeks
  9. Part 2B: Number of Participants With Any Adverse Event Leading to Withdrawal From the StudyTime frame: Up to maximum 33 weeks
  10. Part 1: Number of Participants With Dose Reductions or DelayTime frame: Up to maximum 39 weeks
  11. Part 2A: Number of Participants With Dose Reductions or DelayTime frame: Up to maximum 105 weeks
  12. Part 2B: Number of Participants With Dose Reductions or DelayTime frame: Up to maximum 33 weeks
  13. Part 1: Number of Participants With Any Grade Change From Baseline in Hematology ParametersTime frame: Baseline (Day 1) and up to maximum 39 weeks
  14. Part 2A: Number of Participants With Any Grade Change From Baseline in Hematology ParametersTime frame: Baseline (Day 1) and up to maximum 105 weeks
  15. Part 2B: Number of Participants With Any Grade Change From Baseline in Hematology ParametersTime frame: Baseline (Day 1) and up to maximum 33 weeks
  16. Part 1: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory ParametersTime frame: Baseline (Day 1) and up to maximum 39 weeks
  17. Part 2A: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory ParametersTime frame: Baseline (Day 1) and up to maximum 105 weeks
  18. Part 2B: Number of Participants With Any Grade Change From Baseline in Liver Function Laboratory ParametersTime frame: Baseline (Day 1) and up to maximum 33 weeks
  19. Part 1: Number of Participants With Any Grade Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)Time frame: Baseline (Day 1) and up to maximum 39 weeks
  20. Part 2A: Number of Participants With Any Grade Change From Baseline in SBP and DBPTime frame: Baseline (Day 1) and up to maximum 105 weeks
  21. Part 2B: Number of Participants With Any Grade Change From Baseline in SBP and DBPTime frame: Baseline (Day 1) and up to maximum 33 weeks
  22. Part 1: Number of Participants With Worst Case Change From Baseline in Heart Rate (HR)Time frame: Baseline (Day 1) and up to maximum 39 weeks
  23. Part 2A: Number of Participants With Worst Case Change From Baseline in HRTime frame: Baseline (Day 1) and up to maximum 105 weeks
  24. Part 2B: Number of Participants With Worst Case Change From Baseline in HRTime frame: Baseline (Day 1) and up to maximum 33 weeks
  25. Part 1: Number of Participants With Worst Case Change From Baseline in Body TemperatureTime frame: Baseline (Day 1) and up to maximum 39 weeks
  26. Part 2A: Number of Participants With Worst Case Change From Baseline in Body TemperatureTime frame: Baseline (Day 1) and up to maximum 105 weeks
  27. Part 2B: Number of Participants With Worst Case Change From Baseline in Body TemperatureTime frame: Baseline (Day 1) and up to maximum 33 weeks
  28. Part 1: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant Electrocardiogram (ECG) FindingsTime frame: Up to maximum 39 weeks
  29. Part 2A: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant ECG FindingsTime frame: Up to maximum 105 weeks
  30. Part 2B: Number of Participants With Worst Case Post-Baseline Abnormal Clinically Significant ECG FindingsTime frame: Up to maximum 33 weeks

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Villejuif, France

  • GSK Investigational Site

    Amsterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.